Hozen MedAsia Inc. is a Philippine registered corporation involved in importation and distribution of a wide range of pharmaceutical, nutraceutical and food supplement finished formulations.

Omeprazole Sodium
40mg Powder for Injection
Proton Pump Inhibitor

Omeprazole Sodium - OMEXOL


Reflux esophagitis; Acid peptic ulcer disease; Zollinger Ellison syndrome; Adjunctive in duodenal ulcers associated with H. Pylori combined with appropriate antibiotic; Prophylaxis of acid aspiration before surgery; Prevention and treatment of NSAID associated ulcers.


Reconstitution with 10ml of sterile water for injection. Use the reconstituted solution immediately.

In patients with dudodenal ulcer, gastric cer or reflux oesophagitis where oral medication is inappropriate, Omeprazole IV 40mg once daily is recommended.

In patients with Zollinge-Ellison syndrome the recommended initial dose of Omeprazole given intravenously is 60mg daily. Higher daily doses may be required and the dose should be adjusted individually. When doses exceed 60mg daily, the dose should be divided and given twice daily.


Known hypersensitivity to omeprazole; Gstric malignancy.


In the presence of any alarm symptom (e.g significant unintentional weight loss, recurrent vomiting, dysphagia, haematemesis or melena) and when gastric ulcer is suspected or present, the possibility of malignancy should be excluded as treatment may alleviate symptoms and delay diagnose.


Due to the decreases intragastric acidity, the absorption of ketoconazole or itraconazole may be reduced during omeprazole therapy as it is during treatment with other acid secretion inhibitors.

As omeprazole is metabolized in the liver through cytochrome P450 it can prolong the elimination of diazepam, phenytoin an warfarin Monitoring of patients receiving phenytoin or warfarin is recommended and a reduction of phenytoin or warfarin dose may be necessary when Omeprazole is added to treatment.

There is no evidence of an interaction with phenacetin, theophylline, caffeine, propranolol, metoprolol, ciclosporin, lidocaine, quinidine, estradiol or antacids when Omeprazole is given orally.

There is no evidence of an interaction with piroxicam diclofenac or naproxen; this is considered useful when patients are required to continue these treatments.


Results from the prospective epidemiological studies indicate no adverse effects of Omeprazole on pregnancy or on the health of the fetus/newborn child. Omeprazole can be used during pregnancy.

Omeprazole is excreted in breast milk but is not likely to influence the child when therapeutic doses are used.


Store at temperature not exceeding 30°C.